These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31217295)

  • 1. IDH Inhibitors Target Common Glioma Mutation.
    Cancer Discov; 2019 Aug; 9(8):992. PubMed ID: 31217295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
    Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
    Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X
    J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
    Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
    Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 inhibitor shows promising early results.
    Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
    Zheng M; Tang R; Deng Y; Yang K; Chen L; Li H
    Bioorg Chem; 2018 Sep; 79():89-97. PubMed ID: 29738972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting the landscape: The role of IDH inhibitors in glioma cell fate.
    Giacobetti SA; Fine HA
    Cancer Cell; 2024 May; 42(5):741-743. PubMed ID: 38579726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Friend or foe-IDH1 mutations in glioma 10 years on.
    Huang LE
    Carcinogenesis; 2019 Nov; 40(11):1299-1307. PubMed ID: 31504231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.
    Zheng M; Sun W; Gao S; Luan S; Li D; Chen R; Zhang Q; Chen L; Huang J; Li H
    Oncotarget; 2017 Jul; 8(27):44255-44265. PubMed ID: 28498812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
    Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
    Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
    Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
    Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
    Silvani A; Franceschi E
    Tumori; 2024 Jun; 110(3):160-161. PubMed ID: 38166539
    [No Abstract]   [Full Text] [Related]  

  • 17. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
    Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
    Zou F; Pusch S; Hua J; Ma T; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem Lett; 2018 Feb; 28(3):388-393. PubMed ID: 29290542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
    Borger DR; Zhu AX
    Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.
    Jakob CG; Upadhyay AK; Donner PL; Nicholl E; Addo SN; Qiu W; Ling C; Gopalakrishnan SM; Torrent M; Cepa SP; Shanley J; Shoemaker AR; Sun CC; Vasudevan A; Woller KR; Shotwell JB; Shaw B; Bian Z; Hutti JE
    J Med Chem; 2018 Aug; 61(15):6647-6657. PubMed ID: 30004704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.